NO20064366L - Tiazolderivat - Google Patents

Tiazolderivat

Info

Publication number
NO20064366L
NO20064366L NO20064366A NO20064366A NO20064366L NO 20064366 L NO20064366 L NO 20064366L NO 20064366 A NO20064366 A NO 20064366A NO 20064366 A NO20064366 A NO 20064366A NO 20064366 L NO20064366 L NO 20064366L
Authority
NO
Norway
Prior art keywords
derivative
salt
phenyl
pyridyl
heteroaromatic ring
Prior art date
Application number
NO20064366A
Other languages
English (en)
Inventor
Hajime Asanuma
Masakazu Sato
Yuko Matsunaga
Hideaki Amada
Takeshi Koami
Tetsuo Takayama
Tetsuya Yabuuchi
Fumiyasu Shiozawa
Hironori Katakai
Hiroki Umemiya
Akiko Ikeda
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of NO20064366L publication Critical patent/NO20064366L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Tiazolylimidazolderivat representert ved formelen hvori X1 og X2 er forskjellig fra hverandre og representerer et svovelatom eller et karbonatom; R1 representerer fenyl, substituert fenyl, fenyl sammensmeltet med en heteroaromatisk ring, en pyridyl eller pyridyl sammensmeltet med en heteroaromatisk ring; R2 representerer hydrogen, halogen, C1-C6 alkyl, C1-C6 alkyl substituert med ett eller flere halogenatomer, C1-C6 alkoksy, C1-C6 alkanoyl eller C1-C5 hydroksyalkyl; og A representerer en gruppe representert ved følgende formel) eller et farmasøytisk akseptabelt salt eller derivat; og en ALK 5 inhibitor, terapeutisk middel for alopeci eller hårgjenoppretter som hver inneholder derivatet eller saltet som en aktiv ingrediens. Derivatet eller saltet er en substans som inhiberer ALK 5, som er en TGB-( type-I-reseptor. Hårvekstpreparatet eller hårgjenoppretterne er basert på en ny funksjon.
NO20064366A 2004-03-05 2006-09-26 Tiazolderivat NO20064366L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004062321 2004-03-05
JP2004344307 2004-11-29
PCT/JP2005/003755 WO2005085241A1 (ja) 2004-03-05 2005-03-04 チアゾール誘導体

Publications (1)

Publication Number Publication Date
NO20064366L true NO20064366L (no) 2006-11-08

Family

ID=34921704

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064366A NO20064366L (no) 2004-03-05 2006-09-26 Tiazolderivat

Country Status (13)

Country Link
US (2) US7678810B2 (no)
EP (1) EP1721905A4 (no)
JP (1) JP4853284B2 (no)
KR (1) KR101150077B1 (no)
AU (1) AU2005219737B2 (no)
BR (1) BRPI0508397A (no)
CA (1) CA2556944C (no)
MY (1) MY146532A (no)
NO (1) NO20064366L (no)
NZ (1) NZ549003A (no)
RU (1) RU2367661C2 (no)
WO (1) WO2005085241A1 (no)
ZA (1) ZA200606734B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
EP1971595B1 (en) * 2005-12-30 2013-10-16 Merck Sharp & Dohme Corp. Cetp inhibitors
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
KR20090053923A (ko) 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
CN101595105B (zh) 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2009227013B2 (en) * 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
WO2010126022A1 (ja) * 2009-04-28 2010-11-04 大正製薬株式会社 イミダゾール誘導体
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
CA2874764C (en) 2012-05-30 2022-11-01 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014197421A1 (en) 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2015371822B2 (en) * 2014-12-24 2020-04-09 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
CA3202332A1 (en) 2015-12-07 2017-06-15 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US11124509B2 (en) * 2017-03-23 2021-09-21 Clavius Pharmaceuticals, LLC. Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
TW202233646A (zh) 2020-10-30 2022-09-01 日商日產化學股份有限公司 包含脂質胜肽與蔗糖酯之組成物
AU2023418987A1 (en) * 2022-12-30 2025-07-03 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
CN116891472A (zh) * 2023-07-13 2023-10-17 延边大学 一种含咪唑结构的酰胺类衍生物及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH032540A (ja) * 1989-05-30 1991-01-08 Shimadzu Corp 漏れ試験方法とパッケージ形電子ディバイス
US5338856A (en) * 1992-08-17 1994-08-16 Dowelanco 3,4-N,trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
JP3714633B2 (ja) 1993-08-24 2005-11-09 塩野義製薬株式会社 ２−アミノアゾール誘導体
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
JPH08157363A (ja) * 1994-12-02 1996-06-18 Japan Energy Corp 制癌剤
EP0994858A1 (en) 1997-06-30 2000-04-26 Ortho-McNeil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
KR20010041812A (ko) * 1998-03-10 2001-05-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 비트로넥틴 수용체 길항제
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
WO2000064894A1 (en) * 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
EP1214303A1 (en) * 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
US6956049B1 (en) * 1999-08-31 2005-10-18 Merck & Co., Inc. Methods of modulating processes mediated by excitatory amino acid receptors
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
JP2001163861A (ja) 1999-12-07 2001-06-19 Nippon Soda Co Ltd ジフェニルイミダゾール化合物および農園芸用殺菌剤
AU2096901A (en) 1999-12-17 2001-06-25 Procter & Gamble Company, The N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
US6486142B2 (en) * 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
JP2004517068A (ja) 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
JP2004525930A (ja) 2001-03-23 2004-08-26 バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング 皮膚関連疾患の治療及び診断のためのＴＧＦ−βスーパーファミリーのサイトカインの使用
EP1395831A2 (en) * 2001-04-19 2004-03-10 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Method for the relative determination of physicochemical properties
JP3726715B2 (ja) * 2001-06-19 2005-12-14 村田機械株式会社 自動ワインダのテンション制御装置
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
WO2003080592A1 (en) * 2002-03-27 2003-10-02 Sumitomo Chemical Company, Limited 2-pyrone compounds and use thereof
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1532118A2 (en) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
WO2004013135A1 (en) * 2002-07-31 2004-02-12 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor

Also Published As

Publication number Publication date
AU2005219737A1 (en) 2005-09-15
WO2005085241A1 (ja) 2005-09-15
BRPI0508397A (pt) 2007-08-07
ZA200606734B (en) 2008-01-08
EP1721905A4 (en) 2009-11-18
AU2005219737B2 (en) 2009-11-19
RU2006135111A (ru) 2008-04-10
MY146532A (en) 2012-08-15
JPWO2005085241A1 (ja) 2008-01-17
KR20060124744A (ko) 2006-12-05
EP1721905A1 (en) 2006-11-15
JP4853284B2 (ja) 2012-01-11
US20070154428A1 (en) 2007-07-05
US7678810B2 (en) 2010-03-16
US20100216787A1 (en) 2010-08-26
NZ549003A (en) 2009-07-31
KR101150077B1 (ko) 2012-06-01
CA2556944C (en) 2012-10-09
CA2556944A1 (en) 2005-09-15
RU2367661C2 (ru) 2009-09-20
HK1104543A1 (zh) 2008-01-18

Similar Documents

Publication Publication Date Title
NO20064366L (no) Tiazolderivat
NO20063446L (no) Tiazolderivater
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
AR043940A1 (es) Inhibidores de sulfonamidas heterociclicas que contienen fluor- y trifluoralquilo de la produccion de beta amiloides y derivados de los mismos
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
NO20080391L (no) Pyrazolbaserte LXR modulatorer
UA91470C2 (ru) Нематоцидная композиция, способ борьбы с нематодами и применение производной n-2-(пиридил) этилкарбоксамида в качестве нематоцида
LU92113I2 (fr) Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA)
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
ES2188016T3 (es) Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas.
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20082917L (no) Oksadiazolderivater med CRTH2-reseptoraktivitet
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
NO20060219L (no) Forbindelser
NO20074718L (no) BCRP/ABCG2 inhibitor
NO20053133L (no) Kjemiske forbindelser.
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NO20065733L (no) Naftalinderivater nyttige som histamin-3-reseptor ligander
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application